Session Information
Date: Wednesday, June 22, 2016
Session Title: Phenomenology and clinical assessment of movement disorders
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To assess patients with Parkinson’s disease (PwPD) impulsive-compulsive behaviors (ICBs) prevalence compared to healthy controls (HCs) group, to analyze PD clinical features, ICBs risk factors, relationship between ICBs and dopaminergic treatment.
Background: ICBs are increasingly reported as serious PD dopaminergic treatment side-effects.
Methods: Two groups were studied (homogeneous in age, gender, without dementia): I – 266 PwPD, II – 236 HCs. Clinical assessments were studied using detailed analysis of epidemiology, demographic data (age, sex), disease onset, disease duration, PD symptoms, risk factors, ICBs presence, dopaminergic treatment, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease–Rating Scale (QUIP-RS), Hospital Anxiety and Depression Scale, Beck depression inventory II, Epworth Sleepiness Scale, Apathy Scale, The Short Form-36, in PwPD – United Parkinson’s disease Rating Scale (III part). We analyzed the clinical features and data related to the PD group treatment. The statistical analysis includes Chi-Square, T-student and Pearson correlation coefficient.
Results: ICBs were more frequent in the PD group (p<0.05). Compulsive eating (6.8% in I group, 0.9% in II), punding-hobbyism (10.5% and 2.5% respectively) and hypersexuality (4.9%, 2.1%) were more prevalent while gambling (3.8%, 1.7%) and compulsive shopping (3.4%, 1.7%) occurred less frequently in both groups. Dopamine Dysregulation Syndrome was only in PwPD group (8.7%). Significantly ICBs risk factors were younger age (p=0.046), PD onset earlier age (p=0.014), longer PD duration (p=0.001), male gender (p=0.036), increased rate of motor and non-motor fluctuations (p=0.039), use of dopamine agonist or amantadine therapy (p=0.003), L-dopa high dose (p=0.016).
Conclusions: Prevalence of ICBs in PwPD was the result of dopaminergic therapy. Risk factors of ICBs should be considered in dopaminergic therapy for correct strategy treatment.
To cite this abstract in AMA style:
M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, N.G. Brazovskaya, S.E. Sukhanov. Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/impulsive-compulsive-behaviors-in-patients-with-parkinsons-disease-and-demographically-comparable-group-of-healthy-controls/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/impulsive-compulsive-behaviors-in-patients-with-parkinsons-disease-and-demographically-comparable-group-of-healthy-controls/